Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia

@article{Miller1993LossOS,
  title={Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia},
  author={Robert Miller and Guy Chouinard},
  journal={Biological Psychiatry},
  year={1993},
  volume={34},
  pages={713-738}
}
Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients
TLDR
Disclosure of genetic predictors of the development of AIP and AITD, as the most common neurological adverse drug reactions (ADRs) in the treatment of patients with psychiatric disorders, may provide a key to thedevelopment of a strategy for personalized prevention and treatment of the considered complication of AP therapy for schizophrenia in real clinical practice.
Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias
TLDR
Findings further support evidence of the possible involvement of the cholinergic system and the ventrolateral striatum in VCMs, and possibly TD.
Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 1: Pathophysiology and Mechanisms of Induction
TLDR
It is plausible that several of these vulnerabilities and mechanisms act together to produce TD, and the lower incidence of TD with atypical antipsychotics has helped to elucidate the mechanisms of TD.
New Models of Frontal-Subcortical Skeletomotor Circuit Pathology in Tardive Dyskinesia
  • W. Marchand, V. Dilda
  • Psychology, Medicine
    The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
  • 2006
TLDR
This work has shown that the focused selection model of skeletomotor circuit function provides a compelling model of neurocircuit abnormalities in TD and may lead to the development of better treatment and prevention strategies for this disorder.
The neuropathological effects of antipsychotic drugs
Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials
TLDR
Effective adjunctive treatment for the symptoms of TD will depend on gaining a better understanding of the neurological changes induced by chronic dopamine D2 receptor antagonism from APs.
Is schizophrenia a dopamine supersensitivity psychotic reaction?
  • M. Seeman, P. Seeman
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2014
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission
TLDR
The immune-mediated glutamatergic-dopaminergic dysregulation may lead to the clinical symptoms of schizophrenia and the use of antiinflammatory cyclo-oxygenase-2 inhibitors, which can also decrease KYNA directly, are discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 257 REFERENCES
Pharmacological modification of experimental tardive dyskinesia.
TLDR
It is concluded that dopamine receptor blockade, as well as increased activity within the GABA-ergic or cholinergic systems cause alleviation of TD, in agreement with earlier reports in man and thus seem to validate this primate model.
Abnormal Involuntary Movements in Schizophrenia: Are They Related to the Disease Process or Its Treatment? Are They Associated with Changes in Dopamine Receptors?
TLDR
It is concluded that dyskinetic changes occur as a consequence of the process of schizophrenia and perhaps other diseases, and ligand binding to D-2 receptors was increased in patients with schizophrenia in comparison with controls.
The pharmacology of tardive dyskinesias.
  • H. Klawans
  • Psychology, Medicine
    The American journal of psychiatry
  • 1973
TLDR
It has been demonstrated that anticholinergic drugs worsen tardive dyskinesias in patients who have this disorder and that centrally active antICHolinergic agents should not be used as a routine adjunct to neuroleptic therapy.
Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage
  • J. Schneider
  • Psychology, Biology
    Pharmacology Biochemistry and Behavior
  • 1989
Tardive dyskinesia and depressive illness.
TLDR
Ch Chronically decreased neurotransmission in the synapse of a patient with depression may contribute to the development of a super-sensitive receptor and could explain the high proportion of patients with depression seen in this sample of Patients with tardive dyskinesia.
Severe cases of neuroleptic-induced supersensitivity psychosis Diagnostic criteria for the disorder and its treatment
Levodopa-Induced Dyskinesia: Facts and Fancy. What Does the MPTP Monkey Model Tell Us?
TLDR
It appears that no single receptor is the sole culprit, that some form of denervation supersensitivity is probably involved but not in the form of increased density of dopamine receptors, and the MPTP monkey model remains very useful for predicting the potential of new drugs for inducing dyskinesia.
The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
TLDR
The treatment and patient variables that may be considered as risk factors for tardive dyskinesia are discussed and some of the inconsistencies in the relevant literature may be explained by a speculative sub-classification of tardives dyskine into early and late forms.
Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.
TLDR
Findings provide further evidence that nigrostriatal damage is essential for the genesis of L-DOPA-induced dyskinesias and suggest behavioural supersensitivity in MPTP-treated monkeys.
...
1
2
3
4
5
...